The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to misleading statements about the company's growth potential and subsequent stock price decline [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 8, 2024, to May 8, 2025 [3]. - Allegations include that Iovance provided overly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. - The company announced reduced revenue guidance for fiscal year 2024 due to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [3]. Stock Price Impact - Following the announcement of reduced guidance, Iovance's stock price fell from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, representing a decline of approximately 44.795% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated stock prices [5].